IP Library › Granted Patent US 12,734,795
Granted Patent B2
US 12,734,795 · App. 18/667,327 · Granted Sep 15, 2026

Method and apparatus for printing radiopaque indicia

Inventors: Mark S. Fisher (Sellersville, PA); Raymond D. Hawley (East Greenville, PA)
Assignee: Medical Components, Inc.
B41F17/001A61M39/0208C09D11/02A61M2039/0238B41M1/10B41M1/22B41M7/00B41M7/009
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,734,795
App. No.
18/667,327
Granted
Sep 15, 2026
Kind
B2
Abstract

A method of printing radiopaque indicia on a medical device. The method includes applying radiopaque marking fluid to a surface of a plate comprising one or more etchings having a depth of at least 0.0001 inches, exposing the radiopaque marking fluid on the surface of the plate to air to allow the radiopaque marking fluid to achieve a sufficient level of tackiness, and transferring the radiopaque marking fluid to a medical device. The radiopaque marking fluid comprises a clear ink and tungsten particulates having a particulate size of more than one micron.

Claims (20)

1 . A method of manufacturing a venous access port having printed indicia, the venous access port comprising:

a housing that includes an interior fluid reservoir;

a septum; and

a discharge port extending from the reservoir;

the method of manufacturing comprising:

(a) positioning the venous access port on a jig, wherein the jig comprises a plate having at least one recess configured to hold the venous access port;

(b) applying radiopaque marking fluid to a surface of a plate comprising one or more etchings having a depth between 0.0001 inches and 0.003 inches, wherein the radiopaque marking fluid comprises a clear ink and tungsten particulates having at least one particulate size more than 1 micron and no more than 5 microns;

(c) depositing the radiopaque marking fluid onto a surface of the plate around the one or more etchings and into the one or more etchings by placing an inverted cup containing the radiopaque marking fluid onto the surface of the plate over the one or more etchings, the inverted cup comprising a ring that is compressed against the plate due to an attraction by a plurality of magnets disposed on a riser of the inverted cup when the inverted cup is placed onto the surface of the plate, the ring being a structure that circumvents a perimeter of the inverted cup and the riser being a member positioned at a central point of the inverted cup, wherein the plurality of magnets comprises at least four magnets positioned concentrically within the ring and located equidistant from each other;

(d) wiping the radiopaque marking fluid deposited onto the surface of the plate around the one or more etchings off the surface of the plate around the one or more etchings by translating the inverted cup so as to cause the ring to slide along the surface of the plate away from the one or more etchings, thereby exposing the radiopaque marking fluid deposited within the one or more etchings to air to allow the radiopaque marking fluid to achieve a sufficient level of tackiness; and

(e) picking up some of the radiopaque marking fluid deposited within the one or more etchings using a silicone pad and transferring the picked up radiopaque marking fluid to the venous access port, the silicone pad having a firmness to facilitate transfer of as much of the radiopaque marking fluid deposited within the one or more etchings to the venous access port that will adhere to the venous access port;

wherein the steps of applying, exposing, and transferring are an application of the radiopaque marking fluid, the application being repeated to achieve an amount of the radiopaque marking fluid on the venous access port having at least a predetermined radiopacity.

2 . The method of manufacturing of claim 1 , wherein the at least one X-ray discernable indicium comprises letters “CT” and the one or more etchings comprise letters “CT”.

3 . The method of manufacturing of claim 1 , wherein exposing the radiopaque marking fluid deposited within the one or more etchings to air to allow the radiopaque marking fluid to achieve a sufficient level of tackiness further comprises blowing chilled air onto the marking fluid.

4 . The method of manufacturing of claim 1 , wherein exposing the radiopaque marking fluid deposited within the one or more etchings to air to allow the radiopaque marking fluid to achieve a sufficient level of tackiness further comprises blowing heated air onto the marking fluid.

5 . The method of manufacturing of claim 1 , wherein exposing the radiopaque marking fluid deposited within the one or more etchings to air to allow the radiopaque marking fluid to achieve a sufficient level of tackiness further comprises blowing ambient air onto the marking fluid.

6 . The method of manufacturing of claim 1 , wherein the ratio of the clear ink and the tungsten particulates is determined according to a durometer, a chemical makeup and the processing of the material of the venous access port on which the radiopaque marking fluid is to be applied.

7 . The method of manufacturing of claim 1 , wherein a ratio of the clear ink and the tungsten particulates is determined according to a material of the venous access port on which the radiopaque marking fluid is to be applied.

8 . The method of manufacturing of claim 1 , wherein the transferring of the picked up radiopaque marking fluid to the venous access port comprises transferring of the picked up radiopaque marking fluid to a bottom surface of the housing.

9 . The method of manufacturing of claim 8 , wherein the method results in the bottom surface of the housing being printed with at least one X-ray discernable indicium.

10 . The method of manufacturing of claim 1 , wherein the printed radiopaque marking fluid indicates by visual inspection of the printed venous access port prior to being implanted into a patient, and by X-ray examination after being implanted into a patient, that the venous access port is capable of high-pressure injection.

Continuity (4)
Continuation 17181496 · Feb 22, 2021
Continuation 13101878 · May 5, 2011
Provisional Application 61331671 · May 5, 2010
Related Publication 20240336058A1 · Oct 10, 2024
References Cited (84)
US 4027391A · Samis · 1977 [cited by applicant]
US 4181132A · Parks · 1980 [cited by applicant]
US 4560375A · Schulte · 1985 [cited by applicant]
US 4673394A · Fenton, Jr. et al. · 1987 [cited by applicant]
US 4863470A · Carter · 1989 [cited by applicant]
US 4928298A · Tanaka · 1990 [cited by applicant]
US 5045060A · Melsky et al. · 1991 [cited by applicant]
US 5203777A · Lee · 1993 [cited by applicant]
US 5237922A · Ho · 1993 [cited by applicant]
US 5322511A · Armbruster et al. · 1994 [cited by applicant]
US 5423334A · Jordan · 1995 [cited by applicant]
US 5632205A · Gordon et al. · 1997 [cited by applicant]
US 5662600A · Watson et al. · 1997 [cited by applicant]
US 5806419A · Adner et al. · 1998 [cited by applicant]
US 6213973B1 · Eliasen et al. · 2001 [cited by applicant]
US 6287293B1 · Jones et al. · 2001 [cited by applicant]
US 6314880B1 · Lampinski · 2001 [cited by applicant]
US 6356621B1 · Furumori et al. · 2002 [cited by applicant]
US 6459772B1 · Wiedenhoefer et al. · 2002 [cited by applicant]
US 6527754B1 · Tallarida et al. · 2003 [cited by applicant]
US 7785302B2 · Powers · 2010 [cited by applicant]
US 8257325B2 · Schweikert et al. · 2012 [cited by applicant]
US 10179230B2 · Powers et al. · 2019 [cited by applicant]
US 20020152903A1 · Adner · 2002 [cited by applicant]
US 20040019266A1 · Marciante et al. · 2004 [cited by applicant]
US 20040068315A1 · Chandrasekaran et al. · 2004 [cited by applicant]
US 20040157952A1 · Soffiati · 2004 [cited by applicant]
US 20050065434A1 · Bavaro · 2005 [cited by examiner]
US 20070233017A1 · Zinn · 2007 [cited by examiner]
US 20070270770A1 · Bizup · 2007 [cited by applicant]
US 20070272098A1 · Lutz · 2007 [cited by applicant]
US 20080131593A1 · Powell · 2008 [cited by applicant]
US 20080319399A1 · Schweikert et al. · 2008 [cited by applicant]
US 20090264990A1 · Bruszewski et al. · 2009 [cited by applicant]
US 20100096596A1 · Lewis · 2010 [cited by applicant]
US 20190252603A1 · Wiley et al. · 2019 [cited by applicant]
US 20190275311A1 · Hibdon et al. · 2019 [cited by applicant]
CN 1901940A · 2007 [cited by applicant]
EP 1238682A2 · 2002 [cited by applicant]
EP 1896117B1 · 2011 [cited by applicant]
JP H0199283A · 1989 [cited by applicant]
JP H0284349A · 1990 [cited by applicant]
JP 2006500087A · 2006 [cited by applicant]
MX 2008014737A · 2008 [cited by applicant]
WO WO2004004800A2 · 2004 [cited by applicant]
“Medical Imprinting Is Too Critical to Do In-House”; CI Medical Imprinting Technology, Inc.; 1 page. [cited by applicant]
“Radiopaque Imprinting Enables Alternative to Angioplasty”; Medical Product Manufacturing News; Apr. 2003; 1 page. [cited by applicant]
“Radiopaque Ink on Implantable Medical Devices Provides X-Ray Vision to Surgeons”; CI Medical, Inc.; Sep. 27, 2010; 2 pages. [cited by applicant]
Bill of Materials; 4.8F Low Profile Port Base Annealed—Purple; Radipaque Ink—Black; 1 page. [cited by applicant]
Extended European Search Report for European Application No. EP 17187448.0 dated Dec. 18, 2017, 10 pages. [cited by applicant]
Bill of Materials; M-Port Base—Purple; Radipaque Ink—Black; 1 page. [cited by applicant]
Carlson et al., “Safety Considerations in the Power Injection of Contrast Media via Central Venous Catheters During Computed Tomographic Examinations”, Investigative Radiology, vol. 27, No. 5, May 1992, pp. 337-340. [cited by applicant]
Certificate of Compliance; Purchase Order No. P29319; dated Nov. 21, 2006; 1 page. [cited by applicant]
Certificate of Compliance; Purchase Order No. P34331-00; dated Jun. 17, 2008; 1 page. [cited by applicant]
CI Medical Imprinting Technology, Inc.; Radiopaque Ink—Developed for medical/diagnostic applications; 2 pages. [cited by applicant]
Correspondence from T. Schweikert to B. Mahan dated Sep. 22, 2010; re: Press Releases; 1 page. [cited by applicant]
Coyle et al., “Power Injection of Contrast Media via Peripherally Inserted Central Catheters for CT”, The Journal of the Association for Vascular Access (JAVA), vol. 15, No. 8, Aug. 2004, pp. 809-814. [cited by applicant]
E-mail communication from B. Mahan to R. Bizup dated Jul. 26, 2006, 4:32 p.m.; re: Radiopaque Printing; 2 pages w/attachment. [cited by applicant]
E-mail communication from C. Linden to B. Mahan dated Sep. 24, 2008, 11:37 a.m.; re: Additional Questions; 1 page. [cited by applicant]
E-mail communication from C. Linden to B. Mahan dated Sep. 26, 2008, 12:33 p.m.; re: Medcomp 6 6 process; 2 pages. [cited by applicant]
E-mail communication from D. Kunin to B. Mahan dated Oct. 21, 2008, 2:57 p.m.; re: Question concerning Tungsten; 1 page. [cited by applicant]
E-mail communication from J. Callow to B. Mahan dated Oct. 16, 2008, 2:09 p.m.; re: Tungsten Leaching; 3 pages. [cited by applicant]
E-mail communication from L. Weikert to B. Mahan dated Jan. 2, 2008, 9:52 a.m.; re: Radiopaque Ink; 2 pages. [cited by applicant]
E-mail communication from R. Bizup to B. Mahan dated Jul. 24, 2006, 5:04 p.m.; re: Radiopaque Printing; 2 pages w/attachment. [cited by applicant]
E-mail communication from R. Bizup to B. Mahan dated May 13, 2009, 11:16 a.m.; re: samples; 1 page. [cited by applicant]
Guidance for Industry and FDA Staff, Use of Symbols on Labels and in Labeling of In Vitro Diagnostic Devices Intended for Professional Use, Nov. 30, 2004, 12 pages. [cited by applicant]
Guidance on Medical Device Patient Labeling; Final Guidance for Industry and FDA Reviewers, Apr. 19, 2001, 54 pages. [cited by applicant]
Herts et al., “Power Injection of Contrast Media Using Central Venous Catheters: Feasibility, Safety and Efficacy”, AJR:176(2), Feb. 2001, pp. 447-453. [cited by applicant]
Herts et al., “Power Injection of Intravenous Contrast Material Through Central Venous Catheters for CT: In Vitro Evaluation”, Radiology, vol. 200, No. 3, Sep. 1996, pp. 731-735. [cited by applicant]
International Application No. PCT/US2011/035424, International Search Report, dated Aug. 17, 2011, 2 pages. [cited by applicant]
International Application No. PCT/US2011/035424, Written Opinion, dated Aug. 17, 2011, 4 pages. [cited by applicant]
IsoMed Constant-Flow Infusion System (Year: 2000), 111 pages. [cited by applicant]
Purchase Order No. P29319-00; Printed M-Port Base; dated Nov. 13, 2006; 1 page. [cited by applicant]
Purchase Order No. P34331-00; Re: Printed 4.8F Low Profile Port Base; dated Jun. 9, 2008; 1 page. [cited by applicant]
Reminders from FDA Regarding Ruptured Vascular Access Devices from Power Injection, Jul. 2004, 2 pages. [cited by applicant]
Salis et al., “Maximal Flow Rates Possible during Power Injection through Currently Available PICCs: An In-Vitro Study”, Journal of the Association for Vascular Access, vol. 15, No. 3, Mar. 2004, pp. 275-281. [cited by applicant]
Sawyer, “Do It by Design: An Introduction to Human Factors in Medical Devices”, U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Devices and Radiological Heal… [cited by applicant]
Signs, Symbols, and Icons: Pre-history to the Computer Age, author: Rosemary Sassoon and Albertine Gaur, first published in 1997, 1997, 3 pages. [cited by applicant]
Stevens et al., “A Randomized, Prospective Trial of Conventional Vascular Ports vs. The Vortex “Clear-Flow” Reservoir Port in Adult Oncology Patients”, The Journal of Vascular Access Devices, 2000, pp. 37-40. [cited by applicant]
U.S. Appl. No. 60/658,518, filed Mar. 4, 2005, 78 pages. [cited by applicant]
U.S. Appl. No. 60/675,309, filed Apr. 27, 2005, 100 pages. [cited by applicant]
Work Order Cover Sheet; Purchase Order No. P29319; dated Nov. 16, 2006; 1 page. [cited by applicant]
Work Order Cover Sheet; Purchase Order No. P34331-00; dated Jun. 11, 2008; 1 page. [cited by applicant]
Written Opinion received for PCT Patent Application No. PCT/US2011/035424, dated Aug. 17, 2011, 4 pages. [cited by applicant]